The Race is On! Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

For patients with overweight or obesity and type 2 diabetes seeking weight reduction and improved glycemic control, the REDEFINE 2 study supports cagrilintide-semaglutide as an effective option. But is it better than other incretin-based therapies already available?

Guests: Francesca Reilly, PharmD, Rebecca Munger, PharmD, BCACP, and Jason Zupec, PharmD, BCACP

Music by Good Talk